当前位置: 首页 > 期刊 > 《心脑血管病防治》 > 2019年第2期
编号:13346109
非瓣膜性心房颤动患者抗凝治疗的现状分析(3)
http://www.100md.com 2019年4月1日 《心脑血管病防治》 2019年第2期
     [8]Kirchhof P, Schmalowsky J, Pittrow D, et al. Management of patients with Atrial fibrillation by Primary-Care physicians in Germany: 1-year Results of the ATRIUM Registry[J]. Clin Cardiol,2014,37(5):277-284.

    [9]CBenefit hungwah S, Hungfat T. Net Clinical Benefit of Warfarin therapy in Elderly Chinese Patients With Atrial Fibrillation[J]. Circ Arrhythm Electrophysiol,2014,7(2):300-306.

    [10]Agarwal M, Apostolakis S, Lane DA, et al. The impact of heart failure and left ventricular dysfunction in predicting stroke, thromboembolism, and mortality in atrial fibrillation patients: A Systematic Review[J]. Clinical Therapeutics,2014,36(9):1135-1144.

    [11]Macedo AF, Bell J, Mc Carron C, et al. Determinants of oral anticoagulation control in new warfarin patients:analysis using data from Clinical Practice Research Datalink[J]. Thrombosis Research,2015,36(1):745.

    [12]張乃奇.华法林预防非瓣膜性房颤患者并发脑梗塞的临床分析[J].中外医学研究,2012,10(7):32-33.

    [13]Niamh Hannon, Ethem M, Arsava, et al. Antithrombotic treatment at onset of stroke with atrial fibrillation, function outcome and fatality: a systematic review and meta-analysis[J]. Systematic Review,2015,10(6):806-814.

    [14]于红,王斌,张春丽.心房颤动患者血栓栓塞危险分层及抗血栓治疗临床分析[J].中华临床医师杂志(电子版),2012,6(1):40-42.

    (收稿日期:2018-10-27), http://www.100md.com(夏丽萍 陈建明 潘琳 丁海燕 田亚萍 张书宁)
上一页1 2 3